03 September 2009
Christopher Spillane
christopher.spillane@informausa.com
Metabasis Therapeutics' CEO Dr Mark Erion has resigned from his post to join Merck & Co. Dr Erion, who was also president and chief scientific officer, informed the board of his decision last week and will leave Metabasis on October 31st, after 10 years at the company.
Dr Erion will move...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Amira asset DP2 blockers spun out, not part of BMS $325 million buyout
- California's loss is New Jersey's gain in Ipsen US expansion move
- AMAG hires Jefferies & Co to review options after shareholders nixed Allos merger plan
- Stem cell death for cash-crunched Geron, Angiotech, but Mesoblast outlasts them
FEATURES
- DKSH highlights one-stop benefits as it builds Asia market expansion services
- Merck BioVentures: where biosimilars make a difference
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
